Rhythm Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-02-01
- Employees
- 226
- Market Cap
- -
- Website
- http://www.rhythmtx.com
- Introduction
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity
- Conditions
- Bardet-Biedl SyndromePCSK1 Deficiency ObesityLEPR Deficiency ObesityPOMC Deficiency Obesity
- Interventions
- First Posted Date
- 2021-07-19
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04966741
- Locations
- 🇺🇸
Columbia University Medical Center, Division of Pediatric Endocrinology, Diabetes and Metabolism, New York, New York, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇬🇧Addenbrooke's Hospital, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, United Kingdom
DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway
- First Posted Date
- 2021-07-15
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 164
- Registration Number
- NCT04963231
- Locations
- 🇺🇸
Ten's Medical Center - Pediatric Endocrinology Clinic, Staten Island, New York, United States
🇺🇸The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Endocrine Associates of Dallas and Plano, Dallas, Texas, United States
Open-Label Study of Setmelanotide in Hypothalamic Obesity
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04725240
- Locations
- 🇺🇸
Children's Minnesota, Saint Paul, Minnesota, United States
🇺🇸Seattle Children's Research Institute, Seattle, Washington, United States
🇺🇸Rady Children's Hospital, San Diego, California, United States
A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal Impairment
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT04348175
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Alliance for Multispecialty Research, LLC, Knoxville, Tennessee, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
- Conditions
- Bardet Biedl Syndrome (BBS)Alström Syndrome (AS)
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT03746522
- Locations
- 🇺🇸
Wr-McCr, Llc, San Diego, California, United States
🇺🇸Columbia University Center, New York, New York, United States
🇺🇸M3 Wake Research, Raleigh, North Carolina, United States
Long Term Extension Trial of Setmelanotide
- Conditions
- Obesity Associated With Defects in Leptin-melanocortin Pathway
- Interventions
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 205
- Registration Number
- NCT03651765
- Locations
- 🇺🇸
Obesity Institute, Geisinger Clinic, Danville, Pennsylvania, United States
🇺🇸Wake Research, Raleigh, North Carolina, United States
🇺🇸Wake Research TN, Chattanooga, Tennessee, United States
An Observational,Prospective Natural History Study of Early-Onset Extreme Obesity Due to Bi-Allelic Loss-of-Function Mutations in the POMC, PCSK1 or LEPR Genes
- Conditions
- PCSK1 Deficiency ObesityLEPR Deficiency ObesityPOMC Deficiency Obesity
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03621007
- Locations
- 🇹🇷
Ege University School of Medicine of Pediatric Endocrinology, Bornova, Turkey
🇹🇷Pediatric Endocrinology and Diabetes Marmara University Hospital, Istanbul, Turkey
🇹🇷Dokuz Eylul Universitesi Tip Fakultesi, Balçova, Turkey
The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry
- Conditions
- Genetic Forms of Extreme Obesity
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 303
- Registration Number
- NCT03479437
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇨🇦University of Alberta, Edmonton, Canada
Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity
- Conditions
- Leptin Receptor Deficiency Obesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-09-19
- Last Posted Date
- 2023-05-23
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03287960
- Locations
- 🇳🇱
Erasmus Medical Center, Rotterdam, Netherlands
🇩🇪University of Ulm, Ulm, Germany
🇨🇦Markham Stouffville Hospital, Markham, Ontario, Canada
Setmelanotide in a Single Patient With Partial Lipodystrophy
- First Posted Date
- 2017-08-25
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT03262610
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States